{"classes":[{"categories":[{"measurements":[{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG000","spread":"NA","value":"90.56"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG001","spread":"NA","value":"116.69"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG002","spread":"NA","value":"559.14"},{"groupId":"OG003","spread":"31.83","value":"442.77"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG004","spread":"NA","value":"513.03"},{"groupId":"OG005","spread":"71.94","value":"660.79"},{"groupId":"OG006","spread":"31.1","value":"853.03"},{"groupId":"OG007","spread":"28.58","value":"1158.66"},{"groupId":"OG008","spread":"27.91","value":"813.87"},{"groupId":"OG009","spread":"35.37","value":"1728.80"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG010","spread":"NA","value":"1248.10"},{"groupId":"OG011","spread":"29.92","value":"1444.42"},{"groupId":"OG012","spread":"38.46","value":"1073.51"},{"groupId":"OG013","spread":"23.05","value":"2335.99"},{"groupId":"OG014","spread":"42.16","value":"1793.39"}]}],"title":"Cmax"},{"categories":[{"measurements":[{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG000","spread":"NA","value":"1.11"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG001","spread":"NA","value":"27.86"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG002","spread":"NA","value":"20.62"},{"groupId":"OG003","spread":"73.07","value":"7.55"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG004","spread":"NA","value":"21.20"},{"groupId":"OG005","spread":"71.79","value":"13.25"},{"groupId":"OG006","spread":"68.40","value":"107.30"},{"groupId":"OG007","spread":"139.83","value":"50.49"},{"groupId":"OG008","spread":"47.67","value":"29.39"},{"groupId":"OG009","spread":"80.33","value":"37.92"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG010","spread":"NA","value":"129.76"},{"groupId":"OG011","spread":"112.42","value":"71.43"},{"groupId":"OG012","spread":"115.67","value":"27.89"},{"groupId":"OG013","spread":"112.80","value":"89.96"},{"groupId":"OG014","spread":"111.14","value":"138.75"}]}],"title":"Cmin"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"18"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"7"},{"groupId":"OG013","value":"16"},{"groupId":"OG014","value":"6"}],"units":"Participants"}],"description":"Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.","id":"OG000","title":"Part 1: GSK525762 5 mg QD"},{"description":"Participants were administered once daily oral dose of 10 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 10 mg QD"},{"description":"Participants were administered once daily oral dose of 20 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 20 mg QD"},{"description":"Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.","id":"OG003","title":"Part 1: GSK525762 30 mg QD MM"},{"description":"Participants were administered once daily oral dose of 40 mg GSK525762.","id":"OG004","title":"Part 1: GSK525762 40 mg QD"},{"description":"Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.","id":"OG005","title":"Part 1: GSK525762 40 mg QD MM"},{"description":"Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.","id":"OG006","title":"Part 1: GSK525762 60 mg QD AML"},{"description":"Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG007","title":"Part 1: GSK525762 60 mg QD NHL"},{"description":"Participants with MM were administered once daily oral dose of 60 mg GSK525762.","id":"OG008","title":"Part 1: GSK525762 60 mg QD MM"},{"description":"Participants with AML were administered once daily oral dose of 75 mg GSK525762.","id":"OG009","title":"Part 1: GSK525762 75 mg QD AML"},{"description":"Participants were administered once daily oral dose of 80 mg GSK525762.","id":"OG010","title":"Part 1: GSK525762 80 mg QD"},{"description":"Participants with AML were administered once daily oral dose of 80 mg GSK525762.","id":"OG011","title":"Part 1: GSK525762 80 mg QD AML"},{"description":"Participants with NHL were administered once daily oral dose of 80 mg GSK525762.","id":"OG012","title":"Part 1: GSK525762 80 mg QD NHL"},{"description":"Participants with AML were administered once daily oral dose of 100 mg GSK525762.","id":"OG013","title":"Part 1: GSK525762 100 mg QD AML"},{"description":"Participants with AML were administered once daily oral dose of 120 mg GSK525762.","id":"OG014","title":"Part 1: GSK525762 120 mg QD AML"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Population. Only those participants with data available at the specified data points were analyzed.","reportingStatus":"POSTED","timeFrame":"Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose","title":"Part 1: Maximum Observed Concentration (Cmax) and Minimum Plasma Concentration (Cmin) of GSK525762 Following Single Dose Administration","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter (ng/mL)"}